- Home
- OMCL vs GENB Comparison
OMCL vs GENB Comparison
Compare OMCL & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMCL | GENB |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | OMCL | GENB |
|---|---|---|
| Price | $43.46 | $14.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $55.83 | $23.20 |
| AVG Volume (30 Days) | ★ 526.9K | 294.5K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $787,309,000.00 | N/A |
| Revenue This Year | $6.77 | N/A |
| Revenue Next Year | $5.22 | $16.58 |
| P/E Ratio | $1,066.63 | ★ N/A |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $22.66 | $11.00 |
| 52 Week High | $51.84 | $14.21 |
Technical Indicators
Market Signals| Indicator | OMCL | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 64.86 | 65.28 |
| Support Level | $43.34 | $11.52 |
| Resistance Level | $46.29 | N/A |
| Average True Range (ATR) | 2.09 | 0.77 |
| MACD | 0.77 | 0.13 |
| Stochastic Oscillator | 69.45 | 81.65 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.